<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142062">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251588</url>
  </required_header>
  <id_info>
    <org_study_id>MACI00809</org_study_id>
    <secondary_id>2009-016970-33</secondary_id>
    <nct_id>NCT01251588</nct_id>
  </id_info>
  <brief_title>Extension Study for Participants of Previous Study MACI00206 [NCT00719576] of MACI® Implant for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle</brief_title>
  <official_title>An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of Matrix-Induced Autologous Chondrocyte Implantation (MACI® Implant) for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vericel Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vericel Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to examine the 5-year efficacy and safety of Matrix-Induced
      Autologous Chondrocyte Implantation (MACI® Implant), compared with arthroscopic
      microfracture, in patients who received study treatment in Genzyme-sponsored study MACI00206
      [NCT00719576] for treatment of symptomatic articular cartilage defects of the femoral
      condyle, including the trochlea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from MACI00206 [NCT00719576] Baseline for the patient's Knee Injury and Osteoarthritis Outcome (KOOS) Pain and Function (Sports and Recreational activities) scores.</measure>
    <time_frame>MACI00206 Baseline to Week 156</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from MACI00206 Baseline for the patient's KOOS Pain and Function (Sports and Recreational activities) scores</measure>
    <time_frame>Up to 260 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance imaging (MRI) assessments of structural repair parameters</measure>
    <time_frame>Up to 260 weeks</time_frame>
    <description>Degree of defect fill based on the thickness of repair tissue; defect fill is to be regarded as the principle MRI indicator of response to treatment
Degree of integration of the repair tissue with adjacent native cartilage
Signal intensity of the repair tissue relative to adjacent native cartilage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve at least a 10-point improvement from MACI00206 Baseline in KOOS Pain and function (sports and recreational activities) scores</measure>
    <time_frame>up to week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients in each treatment group assessed as Treatment Failures</measure>
    <time_frame>up to 260 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average time to treatment failure</measure>
    <time_frame>Up to 260 weeks</time_frame>
    <description>the time to treatment failure will be based on the date that the physician decides that surgical re-treatment of the original index lesion is required relative to the date of the original study surgery (i.e., arthroscopy for microfracture and arthrotomy for MACI implant). Treatment failure is only determined in relation to the original treated defect(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from MACI00206 Baseline in the remaining 3 subscales of the KOOS instrument</measure>
    <time_frame>Up to 260 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from MACI00206 Baseline in the patient's evaluation of overall knee condition using the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form</measure>
    <time_frame>Up to 260 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from MACI00206 Baseline in the patient's evaluation of overall knee condition using the Modified Cincinnati Knee Rating System</measure>
    <time_frame>Up to 260 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from MACI00206 Baseline in the 12-Item Short-Form Health Survey (SF-12) Acute Version 2.0 for the 8 subscales and the physical and mental summary components</measure>
    <time_frame>Up to 260 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from MACI00206 Baseline in the European Quality of Life 5 dimensions (EQ-5D) health state</measure>
    <time_frame>Up to 260 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>up to week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting serious adverse events (SAEs)</measure>
    <time_frame>up to week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants having subsequent surgical procedures (SSPs)</measure>
    <time_frame>up to week 260</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Articular Cartilage Defects</condition>
  <arm_group>
    <arm_group_label>Matrix-Induced Autologous Chondrocyte Implant (MACI® Implant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Microfracture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matrix-Induced Autologous Chondrocyte Implant (MACI® Implant)</intervention_name>
    <description>Implantation</description>
    <arm_group_label>Matrix-Induced Autologous Chondrocyte Implant (MACI® Implant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microfracture</intervention_name>
    <description>Arthroscopic Microfracture</description>
    <arm_group_label>Microfracture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients that received study treatment (MACI implant or microfracture) in the
             MACI00206 [NCT00719576] study.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urazova nemocnice v Brne</name>
      <address>
        <city>Brno</city>
        <zip>662 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Na Bulovce- Department of Orthopaedic Surgery Postgraduate Medical Institute</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Saint-Roch</name>
      <address>
        <city>Montpellier Cedex 2</city>
        <zip>34967</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Maussins-Nollet</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'instruction des Armées Robert Picqué</name>
      <address>
        <city>VILLENAVE d'ORNON cedex</city>
        <zip>33882</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre of Utrecht, Department of Orthopaedics</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic &amp; Traumatology of Motor Organs, Independent Public Clinic Hospital</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Centre of Knee Surgery &amp; Arthroscopy, Regional Hospital of Traumatologic Surgery</name>
      <address>
        <city>Piekary Slaskie</city>
        <zip>41-940</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lekmed Medical Center</name>
      <address>
        <city>Warsow</city>
        <zip>01-480</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kungsbacka Närsjukhus</name>
      <address>
        <city>Kungsbacka</city>
        <zip>434 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford, Nuffield Dept. of Orthopaedic Surgery</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 17, 2015</lastchanged_date>
  <firstreceived_date>November 30, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cartilage legions,</keyword>
  <keyword>Symptomatic focal cartilage defects,</keyword>
  <keyword>Microfracture,</keyword>
  <keyword>MACI,</keyword>
  <keyword>Autologous chondrocyte,</keyword>
  <keyword>Trochlea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cartilage Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
